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12/13 wild-type) and 46 patients right-sided primary 
tumors (of those 27 KRAS codon 12/13 wild-type). left-
sided tumors were associated with significantly longer OS 
(p = 0.016, HR = 0.63) and PFS (p = 0.02, HR = 0.67) as 
compared to right-sided tumors. these effects were present 
in the KRAS codon 12/13 wild-type population (HR OS: 
0.42; HR PFS: 0.54), while no impact of primary tumor 
location was evident in patients with KRAS codon 12/13 
mutant tumors (HR OS: 1.3; HR PFS: 1.01). a significant 
interaction of KRAS status and primary tumor location con-
cerning OS and PFS was observed.
Conclusion Our findings suggest that primary tumor loca-
tion and KRAS codon 12/13 mutational status interact on 
the outcome of patients with mCRC receiving cetuximab-
based first-line therapy. left-sided primary tumor location 
might be a predictor of cetuximab efficacy.
Abstract 
Purpose aIO KRK-0104 investigated first-line therapy 
of metastatic colorectal cancer (mCRC) with cetuxi-
mab, capecitabine and irinotecan versus cetuximab, 
capecitabine and oxaliplatin. this analysis investigated 
the impact of primary tumor location on outcome of 
patients.
Patients and methods left-sided primary tumors were 
defined as tumors from rectum to left flexure, while tumors 
in the remaining colon were regarded right sided. Overall 
survival (OS), progression-free survival (PFS) and response 
rate were correlated with primary tumor location. a Cox 
regression model was used to evaluate interaction between 
primary tumor location and KRAS mutation.
Results Of 146 patients of the aIO KRK-0104 trial, 100 
patients presented left-sided (of those 68 KRAS codon 
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Introduction
the idea of personalized medicine was introduced to the 
treatment of metastatic colorectal cancer (mCRC) when 
KRAS codon 12/13 mutations were identified as negative 
predictors of anti-egFR-antibody (egFR-maB) treatment. 
Consequently, only patients with KRAS codon 12/13 wild-
type tumors were subjected to cetuximab or panitumumab 
treatment (Douillard et al. 2013; Huang et al. 2012; Modest 
et al. 2012; Douillard et al. 2010; Bokemeyer et al. 2011; 
amado et al. 2008). this KRAS codon 12/13 wild-type pop-
ulation already excluded about 40 % of all patients and was 
associated with improved response rates (objective response 
rates, ORRs), progression-free survival (PFS) and overall 
survival (OS) in patients receiving egFR-maBs. However, 
ORR in clinical trials investigating egFR-based first-line 
regimens was usually <60 %, indicating that KRAS codon 
12/13 wild-type alone was not a sufficient condition to pre-
dict response (Douillard et al. 2013; Modest et al. 2012; Van 
Cutsem et al. 2011; De Roock et al. 2010; Stintzing et al. 
2009). the identification of additional negative predictors 
such as KRAS exon 3/4 and NRAS exon 2–4 mutations cre-
ated a new target population for egFR-maBs: patients with 
RaS wild-type tumors. this population comprises about 
50 % of all patients with mCRC with a benefit in median OS 
following egFR-targeted first-line therapy of 5–7 months 
(Douillard et al. 2013; Stintzing et al. 2009).
taking into account that even RaS wild-type tumors 
potentially do not define the perfect marker for response 
to egFR-maBs, additional biomarkers are needed. this 
question was recently addressed by retrospective evalua-
tions of patients receiving cetuximab treatment in further 
treatment lines. the efficacy of cetuximab was determined 
to be modulated by the location of the primary tumor 
(Missiaglia et al. 2013; Brule et al. 2013). Due to this ini-
tial evidence, the question was raised whether the location 
of the primary tumor in colorectal cancer can serve as a 
prognostic marker and potentially as a predictive marker 
for treatment with egFR-maBs. to our knowledge, the 
effect of primary tumor location on outcome has not been 
shown in a mCRC study population receiving first-line 
treatment with cetuximab.
the aIO KRK-0104 trial randomized patients to 
CaPIRI plus cetuximab or CaPOX plus cetuximab. With 
reference to this design, we hypothesized that primary 
tumor location of the left colon might have a favorable 
prognostic effect in patients with KRAS wild-type tumors, 
but not in patients with KRAS mutant tumors.
Methods
Study design
Data for this analysis were obtained from the aIO KRK-
0104 trial. this study was a randomized, multicenter phase 
II trial to investigate the efficacy of cetuximab plus CaPIRI 
versus cetuximab plus CaPOX as first-line chemotherapy 
in patients with mCRC and recruited patients from 2004 to 
2006. the primary analysis and the molecular subgroups 
analysis have been published elsewhere (Modest et al. 
2012; Moosmann et al. 2011). Primary endpoint of the aIO 
KRK-0104 study was ORR. this investigation refers to 
the population of 146 patients with central assessment of 
KRAS/BRAF mutations as published before (Modest et al. 
2012).
Definition of right-sided versus left-sided tumors
the primary tumor location was defined in the study 
reports and was extracted from the central database. 
tumors located in rectum, sigma, descending colon and the 
left flexure were defined as left-sided tumors. all tumors 
from cecum to the distal part of the transverse colon were 
categorized as right-sided tumors.
treatment schedule
In both arms, cetuximab was given at an initial dose of 
400 mg/m2 as a 120-min infusion, followed by weekly infu-
sions of 250 mg/m2 over 60 min. Patients in arm a received 
chemotherapy with CaPIRI (i.e., oral capecitabine 800 mg/
m2 twice daily on days 1 through 14, followed by a 1-week 
rest period plus irinotecan 200 mg/m2 as a 30-min intra-
venous infusion on day 1). In patients older than 65 years, 
doses were further reduced by 20 %. Patients in arm B 
received chemotherapy with CaPOX (i.e., capecitabine 
1,000 mg/m2 twice daily on days 1 through 14, followed by 
a 1-week rest period plus oxaliplatin 130 mg/m2 as a 120-
min intravenous infusion on day 1). treatment cycles were 
repeated every 3 weeks until disease progression or unac-
ceptable toxicity (Moosmann et al. 2011).
Patients
the patient population of the aIO KRK-0104 trial was 
described in recent reports (Modest et al. 2012; Moos-
mann et al. 2011). Patients with BRAF mutant tumors were 
analyzed as KRAS wild-type tumors. One patient present-
ing a tumor with BRAF and KRAS mutation was regarded 
as KRAS mutant in this analysis. In two patients, two pri-
mary tumors were located in the left-sided colon (sigma 
and rectum; descendent colon and sigma); these cases were 
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analyzed as left-sided colorectal cancer. In another patient, 
one primary tumor was located in the right part of the colon 
(cecum), while another primary tumor was observed at the 
left side (rectum); this case was classified as right-sided 
colorectal cancer.
endpoints
the present investigation was performed as an explora-
tory analysis using response rates (ORR = complete and 
partial remission), PFS and OS as parameters for outcome 
in patients with tumors of right-sided and left-sided ori-
gin. tumor assessment was performed every two cycles 
(6 weeks). a final update on overall survival was conducted 
in 2011, and the statistical analysis plan was published in 
detail (Modest et al. 2012; Moosmann et al. 2011).
Statistical analysis
In this retrospective, exploratory investigation, OS and 
PFS were stratified by primary tumor location and were 
estimated using the Kaplan–Meier method. Possible dif-
ferences were evaluated by log-rank test and Cox regres-
sion analysis. a Cox regression model was used to evalu-
ate interaction between primary tumor location and KRAS 
mutation as explanatory variables. χ2 tests compared 
response rates. a p value <0.05 was regarded significant. 
For interaction test, a p value <0.10 was regarded signifi-
cant. SPSS PaSW 21.0 (SPSS Inc., Chicago, Illinois) and 
SaS 9.2 (SaS Institute Inc., Cary, nC, USa) were used for 
statistical analysis.
KRAS mutation detection
KRAS/BRAF testing was performed in a german refer-
ence laboratory for KRAS analysis (University of Munich, 
Department of Pathology) as described before (Modest 
et al. 2012; Moosmann et al. 2011).
Results
Study population and tumor characteristics
In all 146 patients of the pathological analysis-set, the 
primary tumor location was assessable. Out of the full 
population, 100 patients presented with left-sided tumors, 
whereas 46 patients presented primary right-sided tumors. 
In detail, tumors were located in rectum (n = 49), sigma 
(n = 40), descending colon (n = 7), left flexure (n = 2), 
transverse colon (n = 11), ascending colon (n = 18), 
cecum (n = 16) and double primary location (n = 3). Out 
of the 100 patients presenting left-sided colorectal tumors, 
68 tumors presented KRAS codon 12/13 wild-type tumors, 
and 32 tumors had KRAS codon 12/13 mutations. Out of 
46 tumors of right-sided origin, 27 tumors were diagnosed 
with KRAS codon 12/13 wild-type status, while 19 patients 
presented a KRAS codon 12/13 mutant tumor. Distribu-
tion of patients with left-sided versus right-sided tumors 
to the treatment arms of the aIO KRK-0104 trial (CaPIRI 
plus cetuximab/CaPOX plus cetuximab) was comparable 
(52/48 % vs. 50/50 %; table 1). 
Baseline patient characteristics
Baseline patient characteristics are shown in table 1. no 
major imbalances associated with primary tumor loca-
tion in the left or right part of the colon were present in 
our cohort. However, a trend toward more female patients 
was observed in the group of right-sided tumors when 
compared to the group of patients with left-sided primary 
tumors (39 % vs. 23 %, p = 0.05; table 1).
effect of primary tumor location on overall survival (OS)
the whole study population reached a median OS of 
21.1 months. Survival times by exact tumor locations are 
shown in Fig. 1a. If analyzed as right vs. left colon, median 
OS of patients with right-sided tumor was 14.8 months, 
while median OS in patients with left-sided tumor was 
26.3 months (p = 0.016, HR = 0.63), (Fig. 1b). In patients 
with KRAS codon 12/13 wild-type tumors, median OS was 
13.0 months in patients with right-sided versus 29.0 months 
in patients with left-sided mCRC (p < 0.001, HR: 0.42). 
the effect of primary tumor location on OS in patients with 
BRAF V600e mutant tumors seemed consistent with the 
observation in the KRAS codon 12/13 wild-type cohort. In 
patients with KRAS codon 12/13 mutant tumors, no signifi-
cant difference was present when OS of patients with right-
sided and left-sided mCRC was compared (Figs. 1c–d and 
3a). 
effect of primary tumor location on progression-free 
survival (PFS)
Median PFS in all patients was 7.0 months. PFS by exact 
tumor location is shown in Fig. 2a. In patients with right-
sided tumors, median PFS was 5.2 months, and in patients 
with left-sided-tumors, it was 7.8 months (p = 0.02, 
HR = 0.67). If KRAS status was taken into account, in 
accordance to OS, a significant difference in PFS associ-
ated with primary tumor location was only evident in 
patients with KRAS codon 12/13 wild-type tumors (4.6 
vs. 8.4 months, p = 0.007, HR = 0.54), but not in patients 
presenting a mutation in these loci. In patients with BRAF 
mutant mCRC, the effect of primary tumor location seemed 
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again consistent with the effects observed in patients with 
KRAS codon 12/13 wild-type tumors (Figs. 2b–d and 3b). 
Interaction of KRAS codon 12/13 mutation and primary 
tumor location
Cox regression models with hazard ratios for primary 
tumor location, KRAS mutation and interaction respectively 
as explanatory variables were analyzed. For OS, the haz-
ard ratio of primary tumor location was 0.160 in favor of 
left-sided (p = 0.002, 95 % CI 0.050–0.511), 0.640 in favor 
of wild-type (p = 0.159, 95 % CI 0.344–1.191) for KRAS 
mutation, and 0.372 (p = 0.013, 95 % CI 0.171–0.810) 
for interaction between primary tumor location and KRAS 
mutation. For PFS, the hazard ratio of primary tumor loca-
tion was 0.252 in favor of left-sided tumors (p = 0.013, 
95 % CI 0.085–0.745), 0.780 in favor of wild-type 
(p = 0.411, 95 % CI 0.432–1.140) for KRAS mutation, and 
0.487 (p = 0.056, 95 % CI 0.233–1.017) for interaction 
between primary tumor location and KRAS mutation.
Influence of BRAF V600e mutations in this study
In our cohort, BRaF mutation was more frequent in right-
sided compared with left-sided primary tumors (24 vs. 
6 %). after removing BRAF V600e mutant tumors from 
the KRAS codon 12/13 wild-type cohort, median PFS of 
patients with KRAS/BRAF wild-type tumors (n = 79) was 
5.9 months in patients with right-sided versus 8.2 months 
with left-sided tumors (p = 0.47, HR = 0.81). Median OS 
was 16.2 months in patients with right-sided compared with 
27.3 months in patients with left-sided tumors (p = 0.11, 
HR = 0.60; Fig. 3a, b).
effect of primary tumor location on response rate
Response rates were analyzed based on non-missing data 
and did not show significant differences. ORR was 58 % in 
left-sided and 53 % in right-sided tumors (p = 0.70) in the 
whole study population. In KRAS codon 12/13 wild-type 
tumors, right-sided tumors were associated with a lower 
ORR when compared to left-sided tumors (43 % vs. 64 %), 
and this difference did not reach significance (p = 0.12). 
When comparing response rates in patients with KRAS 
codon 12/13 mutant mCRC, ORR was 65 % in right-sided 
and 45 % in left-sided tumors (p = 0.23; table 2). 
Discussion
Personalized treatment of mCRC patients is entering daily 
routine in clinical practice. the more tumor sub-clas-
sifications based on molecular markers are defined, the 
higher the chance is to identify positive and negative pre-
dictors and consequently to specify different strategies of 
therapy. Clinical data have proven that mutant RaS genes 
are negative predictive biomarkers and that patients with a 
KRAS/NRAS mutation do not benefit from an egFR-maB-
based therapy (De Roock et al. 2010; Peeters et al. 2013a, b; 
andre et al. 2013). therefore, mutations of KRAS and 
NRAS represent an established negative predictor of egFR-
maB efficacy. the role of BRAF in first-line treatment of 
mCRC is described as a negative prognostic marker, but 
not as a predictive marker in terms of egFR-maB therapy 
(Douillard et al. 2013). Recently, it has been suggested 
that, in addition to RaS mutations, the primary tumor loca-
tion might play a crucial role for efficacy of egFR-maBs 
(Douillard et al. 2013; Missiaglia et al. 2013).
For this reason, we hypothesized that in the aIO KRK-
0104 trial primary tumor location in the left colon might 
Table 1  Baseline characteristics of patients and tumors









n % n %
Patients 100 68 46 32
Age
Median 63 61 0.50 
Range 32–77 47–74
Sex
Female 23 23 18 39 0.05
Male 77 77 28 61
Performance status (Karnofsky)
100 + 90 73 73 32 70 0.55
80 + 70 25 25 14 30
not reported 2 2 0 0
Prior therapy
Chemotherapy 21 21 5 11 0.17
Radiotherapy 12 12 1 2 0.06
Disease sites
liver 84 84 42 91 0.31
lung 32 32 19 41 0.35
lymph node 30 30 20 43 0.13
Peritoneum 12 12 3 7 0.39
Treatment arm
CaPIRI plus cetuximab 52 52 23 50 0.86
CaPOX plus cetuximab 48 48 23 50
Tumor mutation status
KRAS codon 12/13 wild-type 68 68 27 59
0.35
KRAS codon 12/13 mutant 32 32 19 41
BRAF V600e mutant 6 6 11 24 0.004
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have a favorable prognostic effect in patients with KRAS 
wild-type tumors, but not in patients with KRAS mutant 
tumors when receiving cetuximab-based first-line therapy. 
In fact, OS and PFS differed significantly when compar-
ing left- to right-sided tumors. this effect was driven by 
patients with KRAS codon 12/13 wild-type tumors and 
seemed also present in those patients that presented with 
KRAS codon 12/13 wild-type but BRAF V600e mutant 
tumors. By contrast, in patients with KRAS codon 12/13 
mutant tumors, the primary tumor location was not asso-
ciated with significant differences in terms of OS or PFS. 
this interaction of KRAS mutation and primary tumor loca-
tion was found to be significant for both OS and PFS. no 
significant impact of primary tumor location on response 
rates was observed in this study. taking the difference in 
patients with KRAS wild-type tumors into account (64 % 
vs. 43 % in patients with left-sided vs right-sided primary 
tumor), this could be interpreted as a consequence of miss-
ing sample size for this endpoint.
Our results are supported by a recent analysis of the 
nCIC Ctg CO.17 trial (that investigated cetuximab plus 
best supportive care (BSC) versus BSC alone), which 
reported less striking cetuximab-induced effects in patients 
with KRAS codon 12/13 wild-type, right-sided tumors as 
compared with patients bearing a left-sided tumor (Brule 
et al. 2013). a similar observation was reported by Missia-
glia and colleagues who observed a longer PFS in refrac-
tory patients that received cetuximab treatment if the pri-
mary tumor was left-sided as compared to right-sided 
tumors (Missiaglia et al. 2013).
as described above, we grouped patients in left-sided 
versus right-sided tumors, which included tumors from 
cecum to the distal part of the transverse colon. this dis-
tinction corresponds to the midgut versus hindgut definition 
Fig. 1  Overall survival (OS), a according to exact primary tumor 
location, patients with double primary tumors and with primary 
tumor of left flexure were excluded due to sample size, b according 
to right-sided versus left-sided mCRC, c patients with KRaS codon 
12/13 wild-type tumors, d patients with KRaS codon 12/13 mutant 
tumors
1612 J Cancer Res Clin Oncol (2014) 140:1607–1614
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and is modified counting the total colon transversum as 
right-sided colon. nevertheless, the strict separation of 
different tumor locations is questioned by the “continuum 
hypothesis,” which postulates that molecular features of the 
tumor gradually change along bowel subsides, rather than 
change abruptly at splenic flexure (yamauchi et al. 2012a, 
Fig. 2  Progression-free survival (PFS), a according to exact primary 
tumor location patients with double primary tumors and with primary 
tumor of left flexure were excluded due to sample size, b according 
to right-sided versus left-sided mCRC, c patients with KRaS codon 
12/13 wild-type tumors, d patients with KRaS codon 12/13 mutant 
tumors
Fig. 3  Hazard ratios of 
molecular subgroups, error bars 
indicating the 95 % confidence 
interval. a Overall survival, b 
progression-free survival
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b). as shown in Figs. 1a and 2a, a trend toward specific OS 
and PFS could possibly be derived from the exact primary 
tumor location of the colon, but possibly not according to 
the physiological course of the colon. Clearly, our data con-
cerning this issue are limited by sample size.
as samples from the aIO KRK-0104 trial were only 
tested for KRAS exon 2 codon 12/13 mutations, but not for 
KRAS exon 3, 4 or NRAS mutations, our data might con-
tain a bias of approximately 10 % hidden mutations that 
we cannot identify due to lacking tumor material. In our 
cohort, the impact of left- versus right-sided tumors was 
specifically strong in BRAF mutant tumors. this finding 
might be explainable by sample size and MSI/MSS status 
that is unknown for the tumors of aIO KRK-0104 trial 
cohort. It might have been suspected that the whole side 
effect might be influenced by BRAF/MSI/MSS status, since 
BRAF mutations are known to be more frequent in right-
sided colorectal cancer (Pai et al. 2012; Popovici et al. 
2013). However, even after excluding BRAF mutant tumors 
from the KRAS codon 12/13 wild-type cohort, the strong 
prognostic effect of left-sided primary tumors seemed still 
present (hazard ratio for OS: 0.60). It might be concluded 
that in mCRC BRAF mutation interacts in the left- versus 
right-sided tumor story, but is not the only reason for the 
observed differences.
Our data are limited by several aspects. as discussed 
above, we distinguished between KRAS mutant and non-
mutant only and did not take other RaS mutations into 
account. Furthermore, this study only consists of a rather 
small population that might lead to biases, especially in the 
KRAS mutant cohort. Furthermore, treatment differences 
between oxaliplatin- and irinotecan-treated patients could 
not be excluded.
In conclusion, our data correspond favorably with other 
publications investigating egFR-maB use and primary 
tumor location in mCRC. the interaction of primary tumor 
location and KRAS mutations suggests that primary tumor 
location might be an additional biomarker for egFR-
maBs. Corresponding pathological findings to explain this 
phenomenon are still lacking and could be more complex 
than RaS mutations (Missiaglia et al. 2013; Maus et al. 
2013). Data from randomized phase III trials such as 
CRyStal, PRIMe and FIRe 3 are necessary to draw defi-
nite conclusions concerning the restriction of egFR-mabs 
to patients with RaS wild-type left-sided mCRC.
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